Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A maximum likelihood approach for estimating the QT correction factor using mixed effects model.

Amrik Shah1, Gerald Hajian

  • 1Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. amrik.shah@spcorp.com

Statistics in Medicine
|May 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal Trial.

Journal of medical Internet research·2025
Same author

Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling.

Alimentary pharmacology & therapeutics·2025
Same author

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.

Journal of hepatology·2025
Same author

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Contemporary clinical trials·2019
Same author

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.

Gastroenterology·2007
Same author

Classification of large array surface myoelectric potentials from subjects with and without low back pain.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2005
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
See all related articles

This study introduces a maximum likelihood approach for calculating individual QT interval correction factors, reducing bias in cardiac drug safety assessments. Individualized factors improve sensitivity and reduce bias compared to standard methods.

Area of Science:

  • Pharmacology
  • Cardiology
  • Biostatistics

Background:

  • Assessing drug-induced QT interval prolongation is crucial for cardiac safety.
  • Existing QT correction factors (e.g., Bazett, Fridericia) can introduce bias due to heart rate variability.
  • A need exists for more accurate methods to assess QT interval changes.

Purpose of the Study:

  • To propose and evaluate a maximum likelihood (ML) approach for calculating individual QT interval correction factors.
  • To compare the performance of individual correction factors against standard methods (Bazett, Fridericia, pooled).
  • To advocate for the use of individual correction factors in drug safety evaluations.

Main Methods:

  • Utilized data from a 10-day multiple-dose, placebo-controlled crossover trial with 24 subjects.

Related Experiment Videos

  • Applied ML techniques to fit a random-effects model to QT and heart rate (HR) values.
  • Calculated and compared QT corrected for heart rate (QTc) using Bazett, Fridericia, pooled, and individual correction factors.

    • Main Results:

    • Individual correction factors ranged from 0.19 to 0.41, with a pooled factor of 0.292.
    • Treatment effect assessment on QTc yielded inconsistent results across different correction factors.
    • Individual and pooled factors indicated a significant decrease in QTc, while Bazett's suggested prolongation and Fridericia's showed no change.

    Conclusions:

    • Individualized QT correction factors offer significant advantages in sensitivity and bias reduction compared to Bazett's factor.
    • Graphical analysis supports the superiority of individual correction factors for assessing drug-induced QT prolongation.
    • The use of individual correction factors is recommended for more accurate cardiac safety assessments of new drugs.